




EVOXAG[®]
(cevimeline HCl)
30 mg
Capsules

Mouth-watering
relief...



...for the treatment of dry-mouth symptoms of Sjögren's syndrome

Please see important safety information on reverse.



Important Safety Considerations

- The most frequently reported adverse events associated with the use of cevimeline are dry mouth, dizziness, blurred vision, and a muscarinic agonist (> 10% incidence) in clinical trials of cevimeline include nausea, rhinitis, and diarrhea.
- Cevimeline is contraindicated in patients with uncontrolled glaucoma, narrow-angle glaucoma, or acute iritis and narrow-angle (angle-closure) glaucoma.
- Cevimeline can potentially alter cardiac conduction and cause changes in hemodynamics. Cevimeline should be used with medical supervision to patients with a history of asthma, bronchitis, or chronic obstructive pulmonary disease.
- Cevimeline should be administered with caution because of the possibility of increased risk of nephrolithiasis or cholelithiasis.
- If a patient sweats excessively, they should be advised to avoid heat.
- Caution should be used in patients with reduced liver function.
- Safety and efficacy have not been established in children.

Important Safety Considerations

- The most frequently reported adverse events associated with the pharmacologic action of a muscarinic agonist (>10% incidence) in clinical trials of cevimeline were: excessive sweating, nausea, rhinitis, and diarrhea.
- Cevimeline is contraindicated in patients with uncontrolled asthma, known hypersensitivity to the drug, and in acute iritis and narrow-angle (angle-closure) glaucoma
- Cevimeline can potentially alter cardiac conduction and heart rate and produce transient changes in hemodynamics. Cevimeline should be administered with caution and under close medical supervision to patients with a history of cardiac disease, controlled asthma, chronic bronchitis, or chronic obstructive pulmonary disease
- Cevimeline should be administered with caution to patients taking beta-adrenergic antagonists because of the possibility of conduction disturbances and to patients with a history of nephrolithiasis or cholelithiasis
- If a patient sweats excessively while taking cevimeline, dehydration may develop
- Caution should be advised while driving at night or performing hazardous activities in reduced lighting
- Safety and effectiveness in pediatric patients have not been established
- Cevimeline is metabolized by the P-450 isozymes CYP2D6 and CYP3A3/4. Thus, there may be potential for interaction between cevimeline and other compounds
- Special care should be exercised when cevimeline is taken by geriatric patients, considering the greater frequency of decreased hepatic, renal, or cardiac function

Please also see accompanying full prescribing information.

EVOXAC is a registered trademark of Daiichi Pharmaceutical Co., Ltd.



© 2006 Daiichi Sankyo, Inc.


Printed in USA 9/06

DSEV06-0029

2007


EVOXAG[®]
(cevimeline HCl) 30 mg
Capsules

Mouth-watering
relief...



January

| S | M | T | W | T | F | S |
|----|----|----|----|----|----|----|
| | 1 | 2 | 3 | 4 | 5 | 6 |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 | | | |

February

| S | M | T | W | T | F | S |
|----|----|----|----|----|----|----|
| | | | | 1 | 2 | 3 |
| 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 11 | 12 | 13 | 14 | 15 | 16 | 17 |
| 18 | 19 | 20 | 21 | 22 | 23 | 24 |
| 25 | 26 | 27 | 28 | | | |

March

| S | M | T | W | T | F | S |
|----|----|----|----|----|----|----|
| | | | | 1 | 2 | 3 |
| 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 11 | 12 | 13 | 14 | 15 | 16 | 17 |
| 18 | 19 | 20 | 21 | 22 | 23 | 24 |
| 25 | 26 | 27 | 28 | 29 | 30 | 31 |

April

| S | M | T | W | T | F | S |
|----|----|----|----|----|----|----|
| | 1 | 2 | 3 | 4 | 5 | 6 |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | | | | |

May

| S | M | T | W | T | F | S |
|----|----|----|----|----|----|----|
| | 1 | 2 | 3 | 4 | 5 | |
| 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| 13 | 14 | 15 | 16 | 17 | 18 | 19 |
| 20 | 21 | 22 | 23 | 24 | 25 | 26 |
| 27 | 28 | 29 | 30 | 31 | | |

June

| S | M | T | W | T | F | S |
|----|----|----|----|----|----|----|
| | | | | | 1 | 2 |
| 3 | 4 | 5 | 6 | 7 | 8 | 9 |
| 10 | 11 | 12 | 13 | 14 | 15 | 16 |
| 17 | 18 | 19 | 20 | 21 | 22 | 23 |
| 24 | 25 | 26 | 27 | 28 | 29 | 30 |

July

| S | M | T | W | T | F | S |
|----|----|----|----|----|----|----|
| | 1 | 2 | 3 | 4 | 5 | 6 |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 | | | |

August

| S | M | T | W | T | F | S |
|----|----|----|----|----|----|----|
| | | 1 | 2 | 3 | 4 | |
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | 31 | |

September

| S | M | T | W | T | F | S |
|----|----|----|----|----|----|----|
| | | | | | | 1 |
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 | | | | | | |

October

| S | M | T | W | T | F | S |
|----|----|----|----|----|----|----|
| | 1 | 2 | 3 | 4 | 5 | 6 |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 | | | |

November

| S | M | T | W | T | F | S |
|----|----|----|----|----|----|----|
| | | | | 1 | 2 | 3 |
| 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 11 | 12 | 13 | 14 | 15 | 16 | 17 |
| 18 | 19 | 20 | 21 | 22 | 23 | 24 |
| 25 | 26 | 27 | 28 | 29 | 30 | |

December

| S | M | T | W | T | F | S |
|----|----|----|----|----|----|----|
| | | | | | | 1 |
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 | 31 | | | | | |

...for the treatment of dry-mouth symptoms of Sjögren's syndrome

Please see important safety information on reverse.

Important Safety Considerations

- The most frequently reported adverse events associated with the use of cevimeline in clinical trials of cevimeline as a muscarinic agonist (> 10% incidence) in clinical trials of cevimeline were dizziness, dry mouth, blurred vision, nausea, rhinitis, and diarrhea.
- Cevimeline is contraindicated in patients with uncontrolled asthma, acute angle-closure glaucoma, the drug, and in acute iritis and narrow-angle (angle-closure) glaucoma.
- Cevimeline can potentially alter cardiac conduction and cause changes in hemodynamics. Cevimeline should be used with medical supervision to patients with a history of asthma, bronchitis, or chronic obstructive pulmonary disease.
- Cevimeline should be administered with caution to patients because of the possibility of complications such as nephrolithiasis or cholelithiasis.
- If a patient sweats excessively, they should be advised to avoid heat and direct sunlight.
- Caution should be exercised in patients with reduced lighting conditions.
- Safety and efficacy have not been established in children.
- Cevimeline may interact with other drugs.
- Cevimeline may interact with other drugs.

Important Safety Considerations

- The most frequently reported adverse events associated with the pharmacologic action of a muscarinic agonist (> 10% incidence) in clinical trials of cevimeline were: excessive sweating, nausea, rhinitis, and diarrhea.
- Cevimeline is contraindicated in patients with uncontrolled asthma, known hypersensitivity to the drug, and in acute iritis and narrow-angle (angle-closure) glaucoma
- Cevimeline can potentially alter cardiac conduction and heart rate and produce transient changes in hemodynamics. Cevimeline should be administered with caution and under close medical supervision to patients with a history of cardiac disease, controlled asthma, chronic bronchitis, or chronic obstructive pulmonary disease
- Cevimeline should be administered with caution to patients taking beta-adrenergic antagonists because of the possibility of conduction disturbances and to patients with a history of nephrolithiasis or cholelithiasis
- If a patient sweats excessively while taking cevimeline, dehydration may develop
- Caution should be advised while driving at night or performing hazardous activities in reduced lighting
- Safety and effectiveness in pediatric patients have not been established
- Cevimeline is metabolized by the P-450 isozymes CYP2D6 and CYP3A3/4. Thus, there may be potential for interaction between cevimeline and other compounds
- Special care should be exercised when cevimeline is taken by geriatric patients, considering the greater frequency of decreased hepatic, renal, or cardiac function

Please also see accompanying full prescribing information.

EVOXAC is a registered trademark of Daiichi Pharmaceutical Co., Ltd.



© 2006 Daiichi Sankyo, Inc.

Printed in USA 9/06

DSEV06-0028